Vaccine for Alzheimer’s Disease
While plasma’s therapeutic potential takes center stage in AMBAR®, Grifols is developing an active non-plasma immunotherapy through its Araclon Biotech subsidiary. Araclon is developing an anti-amyloid-beta vaccine – ABVac40 – designed to mount a specific immune response against amyloid beta 40 peptide (Ab40) in its soluble form,8 thus avoiding any interaction at the level of the cell membrane, to treat early-stage Alzheimer’s.
Principal data analyzed from a phase 2 trial has shown an excellent safety and tolerability profile.8 It has also demonstrated a high immune response in patients, characterized by a simultaneous rise in the anti-Ab40 titers and levels of this Ab40 peptide in plasma.
We’re continuing to analyze secondary variable results related to efficacy as well as post hoc analyses to further advance development of the vaccine.